Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Polycystic Ovary Syndrome 3Cardiotoxicity 2Breast Neoplasms 2Weight Gain 1Renal Insufficiency, Chronic 1Neoplasms 1Kidney Neoplasms 1Heart Failure 1Diabetes Mellitus, Type 2 1Carcinoma, Renal Cell 1

Interventions

Echocardiography 4sacubitril and valsartan sodium hydrate drug combination 3Standard of Care 3Nutrition Assessment 3Exercise 3Electrocardiography 3Carvedilol 3dapagliflozin 2Surveys and Questionnaires 2Spironolactone 2Rituximab 2Lenalidomide 2Ivabradine 2Control Groups 2Blood Specimen Collection 2Atorvastatin 2Adrenergic beta-Antagonists 2ziprasidone 1pertuzumab 1pegfilgrastim 1obinutuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1acalabrutinib 1Zolpidem 1Watchful Waiting 1Warfarin 1Vincristine 1Vecuronium Bromide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Heart Failure × empagliflozin × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡